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Abstract
Background: Trachoma is thought to be endemic over large parts of Southern Sudan, but empirical evidence is limited.
While some areas east of the Nile have been identified as highly endemic, few trachoma surveys have been conducted in
the remainder of the country. This study aimed to determine whether trachoma constitutes a problem to public health in
Northern Bahr-el-Ghazal and Unity State, both located west of the Nile.
Methods and Principal Findings: Trachoma rapid assessments (TRA) were conducted between July and September 2009.
Seven villages in Northern Bahr-el-Ghazal State and 13 villages in Unity State were surveyed; an average of 50 children (age
1–9 years) and 44 women (age 15 years and above) were examined per village. Samples for analysis using the APTIMA
Combo-2 nucleic acid amplification test (NAAT) were collected from participants with active trachoma in eight villages in
Unity State. In Northern Bahr-el-Ghazal State, only three children with active trachoma (trachomatous inflammation follicular
(TF) and/or trachomatous inflammation intense (TI)) and two women with trichiasis (TT) were found, in two of the seven
villages surveyed. In Unity State, trachoma was endemic in all thirteen villages surveyed; the proportion of children with
active trachoma ranged from 33% to 75% between villages, while TF in children ranged from 16% to 44%. Between 4% to
51% of examined women showed signs of TT. Samples from active trachoma cases tested using the NAAT were positive for
Chlamydia trachomatis infection for 46.6% of children and 19.0% of women.
Conclusions: Trachoma presents a major problem to public health Unity State, while the disease is of low priority in
Northern-Bahr-el-Ghazal State. Implementation of a population-based prevalence survey is now required in Unity State to
generate baseline prevalence data so that trachoma interventions can be initiated and monitored over time.
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Introduction
Trachoma, caused by ocular infection with the bacterium
Chlamydia trachomatis, is the leading cause of infectious, preventable
blindness worldwide, responsible for an estimated 3.6% of all cases
of blindness [1]. The disease is endemic in 57 countries in Africa,
the Middle East, Central and South America, Asia, Australia and
the Pacific Islands. Globally an estimated 40.6 million people are
living with active trachoma (trachoma inflammation-follicular (TF)
and/or trachoma inflammation-intense (TI)) and 8.2 million with
trachomatous trichiasis (TT) [2]. In 1997, the World Health
Organization (WHO) established the Alliance for the Global
Elimination of Blinding Trachoma by the year 2020 (GET 2020)
to support country implementation of the SAFE strategy. SAFE
stands for Surgical correction of trichiasis, Antibiotics for
treatment of active trachoma infection, Facial cleanliness and
Environmental improvement [3,4]. One of the challenges faced by
trachoma control programmes is to cost-effectively target SAFE to
communities most in need [5].
Trachoma endemic communities are generally located in
remote rural areas of developing countries where access to water,
sanitation and health care is inadequate [5,6].
Geographical remoteness and inaccessibility mean that it is
often difficult and costly to conduct fieldwork in these underserved
areas; consequently there are limited data on the distribution of
trachoma in many endemic countries [2,7]. Southern Sudan
provides one such example; large parts are thought to be trachoma
endemic but data on its distribution and burden are mainly limited
to areas east of the river Nile [8,9]. Most of the surveys conducted
to date reported prevalences of TF in children age 1–9 years well
above 10% [8], thus exceeding the WHO recommended threshold
for mass drug administration (MDA) of antibiotics [3]. However,
areas with little to no trachoma have also been identified,
demonstrating that by no means is all of Southern Sudan
trachoma endemic [10]. Considerable heterogeneity in trachoma
transmission is also indicated on a recently developed trachoma
risk map of Southern Sudan [11]. There is thus a clear need for
further trachoma surveys to confirm which parts of the country
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prioritized for intervention if the prevalence of active trachoma in
children age 1–9 years is 10% or higher, or if the prevalence of
trichiasis in people age 15 years and over is 1% or higher [3].
The trachoma rapid assessment (TRA) method, which uses a
two-stage sampling design to optimally bias sampling toward
communities most likely to have trachoma [12], provides a useful
first step in categorizing areas for intervention [13–17]. TRAs
have been successfully used to determine the presence of trachoma
in a number of countries such as Ethiopia [18], Yemen [19], the
Pacific islands [20] and India [21]. We decided to conduct TRAs
in two states of Southern Sudan for which there were little (Unity
State [22]) to no data (Northern Bahr-el-Ghazal State) on
trachoma, but which are indicated to be at risk of trachoma
transmission [11]. These are also two of the first states targeted by
Southern Sudan’s integrated programme for the control of key
neglected tropical diseases [9], which provides opportunities to
scale up trachoma control.
The purpose of the TRAs was to confirm whether trachoma is a
public health problem in these two suspected endemic areas. In
addition, we aimed to determine the viability of using the
APTIMA Combo-2 nucleic acid amplification tests (NAAT) in a
context such as Southern Sudan. The use of NAATs as an adjunct
to clinical assessments has been suggested for monitoring the
impact of antibiotic MDA, because antibiotic treatment has a
more rapid impact on C. trachomatis infection levels than on
symptoms of clinical disease [23]. The use of laboratory assays to
accurately measure C. trachomatis prevalence before and after
antibiotic MDA is therefore important for monitoring progress




The study protocol received ethical approval from the
Directorate of Research, Planning and Health System Develop-
ment, Ministry of Health (MoH), Government of Southern Sudan.
Clearance to conduct the survey was also obtained from the
respective State MoHs, followed by County Health Departments.
The study was explained to the village chief, household heads,
and each adult participant. Household heads were asked to
provide written consent for the household to participate in the
study, by providing a thumbprint on the consent form after its
contents were read out. If the household head was absent, the most
senior person identified by household members was requested to
provide written consent. Each adult participant provided verbal
consent before participating in the study; for all children
examined, consent was obtained from the guardian or household
head. Households or individuals for whom informed consent was
not given were not included in the survey. Household members
that were unwell were not examined for trachoma, and
examinations were halted if a person appeared to be in obvious
distress. Personal identifiers were removed from the dataset before
analysis.
Study sites
TRAs were conducted between July and September 2009 in
Northern Bahr-el-Ghazal and Unity States, Southern Sudan
(Figure 1 A & B). Northern Bahr-el-Ghazal State is divided into
five counties with an estimated population of 720,898, the majority
of whom are Dinka. Unity State is mainly inhabited by Nuer, and
divided into nine counties with an estimated population of
585,801, according to census data collected in 2008. In Northern
Bahr-el-Ghazal State, TRAs were conducted in seven villages
distributed over five counties, while in Unity State a total of
thirteen villages in eight counties were assessed (Note that revised
county shape files recently released by the United Nations Office
for the Coordination of Humanitarian Affairs in Juba, used to
develop figure 1, are not entirely consistent with the location of
villages as indicated by County Health Departments in 2009). In
Unity State, Payinjar county could not be surveyed due to security
and access issues; for the same reasons only one village was
surveyed each in Mayom and Abiemnhom counties.
Survey design
The TRA methodology used here has been described elsewhere
[12]. The method was designed to quickly and cheaply generate
‘‘worst case estimates’’ on the endemicity of active trachoma and/
or TT in a community and, by extrapolation, in a given
administrative area (e.g. district); the method was not developed
to provide estimates of prevalence. Based on TRA results it should
be possible to exclude areas of no or low endemicity from further
surveys and to target population-based prevalence surveys (PBPS)
to suspected highly endemic areas, generating prevalence
estimates to determine the actual need for control activities and
allow their subsequent monitoring and evaluation.
To generate ‘‘worst case estimates’’ we used a convenience
sampling methodology to identify counties and villages most likely
to be endemic for trachoma. Initially, published and grey literature
was reviewed, and anecdotal information was gathered through
meetings with staff from the State MoH and County Health
Department. The information thus obtained was used to
categorize each county according to the likelihood of trachoma.
In counties where there was no evidence of trachoma being
endemic, one village was selected for the TRA, while two villages
were selected in counties where there was evidence of transmis-
sion. Within each county, the villages most likely to have trachoma
were prioritised for sampling. In counties with no information on
trachoma, villages were chosen on the basis of known risk factors,
such as poor access to water and sanitation [24]; in these counties
sampling was stopped if no trachoma was found in the first village
visited. Geographic areas recently surveyed for blinding trachoma
[22] were excluded from the study.
The survey team was comprised of three permanent staff; a
team leader, one ophthalmologist and one ophthalmic nurse. An
additional two short-term staff to obtain consent from and register
participants, and a driver, were hired in each state. Prior to the
survey, sensitisation visits were conducted in each village. The
study’s purpose and methods were explained to the villagers,
information on the transmission and cause of trachoma was
provided, and photographs of trichiasis were shown. A question-
naire was used to conduct an interview with the village leader, to
gather information on the presence of trachoma in the community
and on various environmental and social risk factors relating to
trachoma transmission. Permission to return and conduct the
survey was requested from the village leader, who was also asked
to mobilise the community and request women and children to
gather at the village central-point at a specific time on the survey
day.
On the survey day, participants were selected from those
gathered at the central point. In most villages all women and
children gathered were included in the study, in an attempt to
enrol a total of 50 women age 15 years and above and 50 children
age 1–9 years in each village. Before registration, each household
head was asked how long their family had been living in the
village; only those who had been resident for over six months were
Trachoma in Southern Sudan
PLoS ONE | www.plosone.org 2 October 2010 | Volume 5 | Issue 10 | e13138registered. Each study participant was assigned an identification
number and her/his age and sex was recorded.
Trachoma examination
Participants were examined for signs of trachoma either by an
experienced ophthalmologist or an ophthalmic clinical officer,
according to the WHO simplified grading system [25]. This
scheme categorises trachoma infection according to five grades:
TF, TI, trachomatous scarring (TS), TT and corneal opacity
(CO). Before the start of the survey, the grading skills of the
clinical officer were verified by the ophthalmologist using a two-
stage assessment. In the first stage it was assessed whether the
clinical officer was able to correctly identify at least 80% of
slides in a given set [26]. Subsequently she was observed
e x a m i n i n g5 0w o m e na n d5 0c h i l d r e ni nt h ef i e l d ,t ov e r i f yt h a t
at least 80% inter-observer agreement was reached with the
ophthalmologist.
During the survey, participants had both eyes examined using a
binocular loupe with 2.06 magnification and a torch. Each eye
was initially examined for CO, as well as for in-turned lashes
characteristic of TT. The upper tarsal conjunctiva was then
examined for active trachoma (TF and/or TI) and TS. Trachoma
signs only had to be present in one eye for the person to be
categorised as suffering from a particular grade of trachoma.
Alcohol-soaked cotton swabs were used to clean the examiner’s
fingers between individual examinations. The visual acuity of
women age 15 years and above was measured using a tumbling E-
chart.
Figure 1. Location of survey area and survey sites. A) Map of Africa showing location of Southern Sudan (grey shaded); B) Map of Southern
Sudan showing location of the two surveyed states, Northern Bahr-el-Ghazal and Unity (grey shaded); C) Detailed map of the surveyed states,
including new county boundaries and the proportion of children age 1–9 years with TF in each surveyed village.
doi:10.1371/journal.pone.0013138.g001
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azithromycin tablets (for adults) or syrup (for those age five years
or younger) and provided with information on face washing and
good hygiene practices. Patients with TT or other significant eye
conditions were referred to the nearest facility offering free eye
surgery.
Collection and analysis of NAAT samples
The APTIMA Combo 2 Unisex Swab Specimen Collection Kit
(Gen-Probe, Inc., San Diego, CA, USA) was used for collection
and analysis of samples to be tested by means of nucleic acid
amplification. This type of NAAT detects rRNA, rather than
DNA, which has been indicated to be more sensitive for detection
of C. trachomatis infection [27,28]. The overall sensitivity and
specificity of the APTIMA Combo-2 assay for detection of C.
trachomatis in genital tract specimens has been reported as 96.1%
and 98.0% respectively [29]. The assay has also been validated for
rectal, pharyngeal, and conjunctival samples, showing 100%
agreement with confirmatory probe assays [30]. Prior studies in
Africa have used this assay for determining the prevalence and
treatment outcomes of trachoma [31].
Delivery of sample collection tubes to the field was delayed,
which meant that samples could only be collected from the final
eight villages surveyed in Unity State. In these villages, an eye
swab was taken from the upper tarsal conjunctiva of one eye of
each study participant with active trachoma, following the method
described by Yang and colleagues [27]. Other than the presence of
active trachoma in that eye, no specific method was used to decide
whether the left or the right eye was examined; this decision was
left to the ophthalmologist. Two types of negative field control
were also collected in each village, from the first women and
children examined with no signs of trachoma, in order to assess
potential field contamination. Samples from two women and two
children were taken for each control type. For ‘type-one’ controls,
the swab was passed over the upper tarsal conjunctiva; for ‘type-
two’ controls the swab was passed 2.5 cm above, but not touching,
the conjunctiva. The samples were stored in collection tubes at
room temperature and processed within 60 days of collection.
Samples were processed according to the manufacturer’s instruc-
tions. An internal quality-control process was conducted during
which 126 positive samples and 16 negative samples were re-
tested. The positive samples that were re-tested were trace positive
samples that abutted fully positive samples. The negative samples
that were re-tested were randomly selected from all the negative
samples. The repeat-tests were conducted by the same individuals
using the same type of assay.
Data management and analysis
Data were verified and entered into the study database, created
in MicrosoftH Office ExcelH2007 at the end of each day, and
double entered after completion of the survey. Range and
consistency checks were conducted for all variables. Data were
analysed in STATA 9.0 (Stata Corporation, College Station, TX,
U.S.A.). The proportion of those examined with each grade of
trachoma and associated 95% confidence intervals were calculated
for children and adults examined at each of the survey sites.
Results
A total of 331 children and 278 women were examined in
Northern Bahr-el-Ghazal State, and 671 children and 605 women
in Unity State. The number of children and women examined in
each village averaged 47 and 40 in Northern Bahr-el-Ghazal State
and 51 and 47 in Unity State, respectively. The average number
examined in Northern Bahr-el Ghazal State was lower, because
the residents of one village had been poorly mobilized; only 14
women and 29 children could thus be examined. Information on
active trachoma in children could not be obtained for three
children (one in Northern Bahr-el-Ghazal and two in Unity State),
who refused to have their second eye examined. Information
regarding presence of TT was recorded for all women examined.
In Northern Bahr-el-Ghazal State, trachoma cases were
identified only in two of the seven villages surveyed (Table 1).
One village, in Aweil Centre county, had three cases of active
trachoma in children (i.e. 6% of study participants (95%CI,
1.25%–16.55%), two of which had TF (Figure 1 C). In the same
village a 55 year old woman showed signs of TT. A second TT
case was identified in a village in Aweil West county, in a woman
age 65 years.
In Unity State, 33% (95%CI, 20.40%–48.41%) to 75%
(95%CI, 61.63%–85.61%) of children examined in each village
showed signs of active trachoma (Table 2). The prevalence of TF
ranged from 16% (95%CI, 7.02%–28.59%) to 44% (95%CI,
30.47%–58.67%) between survey villages (Figure 1 C). Of women
examined, 4% (95%CI, 0.53%–14.84%) to 51% (95% CI,
37.07%–64.65%) showed signs of TT. Four cases of TT in
children age 1–9 years were observed in Unity State; the youngest
child was seven years old.
No visual acuity data were obtained for one (0.4%) of the study
participants in Northern Bahr-el-Ghazal State and for 70 (11.6%)
of participants in Unity State. The majority (n=57) of instances
where visual acuity was not recorded occurred in two villages in
Unity State (Bhou in Mayandit county and Pakur in Rubkuona
county) and was due to time constraints and a limited team size. In
two of the villages surveyed in Northern Bahr-el-Ghazal State,
none of the women examined had bilateral visual impairment (VI)
or blindness, while the proportion of women with bilateral VI in
the remaining villages ranged from 4.0% (95%CI, 0.49%–
13.71%) to 42.9% (95%CI, 28.8%–57.8%), and with bilateral
blindness ranged from 4.0% (95%CI, 0.5%–13.7%) to 24.5%
(95%CI, 13.3%–38.9%).
In Unity State, bilateral VI ranged from 15.6% (95%CI, 6.5%–
29.5%) to 51.9% (95%CI, 37.8%–65.7%). In two of the villages
sampled, none of the women had bilateral blindness. In the
remaining eleven villages, 2.2% (95%CI, 0.1%–11.5%) to 18.5%
(95%CI, 9.3%–31.4%) of women examined suffered from bilateral
blindness.
NAAT results
Eye swabs were taken from 95% (208/220) of children with
active trachoma, and 95% (84/88) of women with active trachoma
(TF and/or TI) in eight villages in Unity State. Of these, 46.6%
(n=97) of children and 19.0% (n=16) of women were positive for
C. trachomatis (Table 3). Control type-one samples were taken from
24 children and 18 women, randomly selected from individuals
with no signs of active trachoma. Of the 24 control type-one
samples from children and the 18 control type-one samples from
women, 12.5% (n=3) and 11.1% (n=2) tested positive for C.
trachomatis, respectively. 27 type-two control samples were also
collected; 14 from women and 13 from children. None of these
samples were positive for C. trachomatis.
Of the 292 individuals with active trachoma tested using the
APTIMA Combo-2 NAAT, 34.0% (n=105) and 77.4% (n=226)
had been diagnosed with clinical signs of TF or TI, respectively.
Of the individuals with TF, 36.9% (31/84) of the children and
4.8% (1/21) of the women were positive for C. trachomatis as
identified by the NAAT. Of the individuals diagnosed with TI,
54.4% (81/149) of the children and 20.1% (16/77) of the women
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confirmed the accuracy of the results, as no false positive or false
negatives were found.
Discussion
The present study set out to determine whether trachoma is a
public health problem in two states of Southern Sudan – Northern
Bahr-el-Ghazal and Unity – and hence provide guidance to the
national trachoma programme on where to target its scarce
resources. If the TRA results are taken as estimates of prevalence
they indicate that all communities surveyed in Unity State
exceeded TF prevalence in children age 1–9 years of 10%, at
which level WHO recommends MDA of antibiotics [3]. This
finding is consistent with results from a PBPS in Mankien payam,
Mayom county, which reported 57.5% prevalence of TF in
children [22] and with the predictions of a trachoma risk map of
Southern Sudan [11]. It is not possible to draw conclusions
regarding trachoma prevalence at state or county level based on
the present results, because survey sites and individuals within
each site were not selected at random and because too few sites
were surveyed in each administrative unit [32,33]. A PBPS is
therefore now required in Unity State to generate baseline data on
trachoma prevalence prior to scaling up of SAFE interventions, so
that the trachoma control programme can be monitored and
evaluated over time.
Northern Bahr-el-Ghazal State on the contrary is not a priority
area for the trachoma control programme, as the low levels of
trachoma found by the TRA indicate that the disease is not a
major public health problem in this state. All villages visited had
been identified by local health authorities as the ones most likely to
have trachoma and it is therefore considered unlikely that any foci
of active trachoma and/or TT were missed. The TRA results
contrast with climate-based predictions of the above mentioned
risk map [11], which indicated that at least some parts of Northern
Bahr-el-Ghazal State may be at risk of trachoma transmission.
This finding highlights an important point made elsewhere, but
often forgotten; the primary use of risk maps is to identify likely
Table 2. Prevalence of trachoma signs in Unity State.





* 95% CI % TF 95% CI
No.
examined % TT 95% CI
Rubkuona Biel Chambarou 48 33.3 20.4–48.4 22.9 12.03–37.3 36 19.4 8.2–36.0
Pakur Pakur 51 56.9 42.3–70.7 15.7 7.02–28.6 51 19.6 9.8–33.1
Koch Ngony Riang1 52 65.4 50.9–78.0 44.2 30.47–58.7 44 38.6 24.4–54.5
Jaak Phangak 57 66.7 52.9–78.6 40.4 27.56–54.2 46 45.7 30.9–61.0
Guit Kadet Kadet 56 51.8 38.0–65.3 28.6 17.30–42.2 46 4.4 0.5–14.8
Nyathor Nyathor 54 57.4 43.2–70.8 29.6 17.98–43.6 43 18.6 8.4–33.4
Mayandit Rupqui Dorinyet 56 75.0 61.6–85.6 26.8 15.83–40.3 53 26.5 15.3–40.3
Bhou Bhou 48 47.9 33.3–62.8 25.0 13.64–39.6 46 6.5 1.7–17.9
Ruweng Jam Jany Mankuor 50 48.0 33.7–62.6 18.0 08.58–31.4 42 33.3 19.6–49.6
Nyel Kamagon 50 60.0 45.2–73.6 22.0 11.53–36.0 44 22.7 11.5–37.8
Abiemnhom Manajoga Wungok 49 42.9 28.8–57.8 28.6 16.58–43.3 50 24.0 13.1–38.2
Mayom Wanguara Pibor 48 56.3 41.2–70.5 33.3 20.40–48.4 49 20.4 10.3–34.3
Leer Adok Thor 50 48.0 33.7–62.6 16.0 7.17–29.1 55 50.9 37.1–64.7
*TF and/or TI.
doi:10.1371/journal.pone.0013138.t002
Table 1. Prevalence trachoma signs in Northern Bahr-el-Ghazal State.





* 95% CI % TF 95% CI
No.
examined % TT 95% CI
Aweil Centre Barmayen Kabat 29 0 0.0–11.9 0 0.0–11.9 14 0 0.0–23.2
Chol South Chamang Moui 50 6 1.3–16.6 4 4.9–13.7 50 2 0.1–10.7
Aweil East Madhol Atuet 50 0 0.0–7.1 0 0.0–7.1 50 0 0.0–07.1
Aweil West Mayom Akuak Rel 50 0 0.0–7.1 0 0.0–7.1 32 0 0.0–10.9
Ayat Malek Dira 50 0 0.0–7.1 0 0.0–7.1 34 2.9 0.1–15.3
Aweil North Malual North Mayom Adhal 49 0 0 0–7.3 0 0.0–7.3 48 0 0.0–7.4
Aweil South Wathmuok Majok 52 0 0.0–6.8 0 0.0–6.9 50 0 0.0–07.1
*TF and/or TI.
doi:10.1371/journal.pone.0013138.t001
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further surveys or intervention unless evidence to the contrary
emerges [34]. Risk maps on their own are not to be used to target
trachoma interventions. To be useful tools, trachoma risk maps
need to be validated locally, and should only be used in
conjunction with other sources of evidence prior to excluding
communities from interventions. Despite the existence of a
trachoma risk map for Southern Sudan, verification of suspected
at-risk areas through TRAs is therefore an essential step in the
process of targeting trachoma control. If TRA results indicate that
trachoma is likely to be meso- to hyper-endemic (as in the case of
Unity State), PBPS should then be conducted to generate baseline
data prior to SAFE intervention. In the case of Southern Sudan,
the prevalence data generated by the PBPS can then be
incorporated into the risk mapping model, further improving its
predictions [11].
While no household-level information regarding trachoma risk
factors was collected, various possible explanations for the
observed difference in trachoma endemicity between Unity and
Northern Bahr-el-Ghazal State may be considered. Cattle
ownership, face-washing practices and high household fly densities
have been identified as trachoma risk factors [24,35], and these
clearly differed at community level between the two states. Village
elders interviewed during community sensitization reported
pastoralism as the main occupation in Unity State, but only in
three of the seven villages surveyed in Northern Bahr-el-Ghazal
State. This difference in cattle ownership is likely to be a reflection
of the different tribal compositions in each state: Northern Bahr-el-
Ghazal State is primarily inhabited by Dinka who generally rely
on both cattle and agriculture as sources of income, whereas Unity
is largely inhabited by the Nuer tribe, which relies more heavily on
a pastoralist livelihood. This reported difference in livelihoods was
confirmed through field observations; compared to villages in
Northern Bahr-el-Ghazal State family compounds in Unity State
contained noticeably more cattle, as well as flies, and families were
often found to be drying cattle dung inside their compounds,
reportedly to burn it as a mosquito repellent. Access to clean water
was also reported to differ, with all but one of the villages in
Northern Bahr-el-Ghazal State having access to a hand pump,
compared to only four of the 13 villages visited in Unity State.
Although these results do not allow any definitive conclusions on
the correlation of potential risk factors and trachoma prevalence,
they are consistent with results from an in-depth study that
included data from Unity State [24].
While prevalence data on clinical signs of trachoma will be
required before SAFE intervention is scaled up in Unity State and
elsewhere, combination of clinical assessments with laboratory
results confirming the presence or absence of C. trachomatis will
become of increasing importance for monitoring of programme
impact. Once antibiotic MDA is being scaled up, it is expected to
rapidly decrease infection levels while the decline in symptoms of
clinical disease will be more gradually. Clinical assessments on
their own would thus underestimate the actual impact on
trachoma transmission.
In the present study, C. trachomatis was confirmed in 38.4% of all
active trachoma cases sampled. This relatively low correlation
between clinical diagnosis and NAAT result is consistent with
other studies and likely to be due to the kinetics of the disease,
rather than problems with the NAAT detection system [5,23].
Trachoma has a four to seven day latent phase during which
patients are infected but are not showing clinical signs. Infection
then cause patent disease of variable duration, with both infection
and clinical signs being present. After infection has been cleared,
clinical signs slowly resolve over a recovery phase that can take
several years [36]. Our result may therefore be at least partially
explained by the fact that some of the examined patients will have
been in the recovery phase, showing clinical signs of trachoma
while being no longer infected with C. trachomatis. In addition, in
some the patients the observed follicles may not have been a sign
of C. trachomatis infection, but may have been caused by other
bacteria, such as Moraxella spp. and Streptococcus pneumonia,o rb y
viral infections, such as adenovirus, Molluscum contagiosum or herpes
simplex [37,38].
As demonstrated by the presence of positive NAAT results in
the type-one control samples it is also possible for C. trachomatis to
be detected in the eyes of individuals that do not show signs of
active trachoma. It is unlikely that this observation is the results of
laboratory contamination, as our internal quality control process
identified no false-positives. It is also unlikely to be the result of
contamination of the samples in the field, because none of the
control type-two samples were positive. Probable explanations are
that individuals from which samples were tested with the APTIMA
Combo-2 NAAT were in the latent phase of the disease or had
low-level, asymptomatic, infections. The NAAT result may also
have been positive because infection detectable with the RNA-
based assay used here can persist in the tarsal conjunctiva after
clinical disease has resolved [23,39,40]. Lastly, the criteria for
clinical diagnosis under the simplified grading system are fairly
narrow; patients with follicles present outside the central part of
the upper tarsal conjunctiva or with fewer than five follicles are not
considered as having signs of trachoma, while they may be infected
with the bacteria [25,37].
The present study had several limitations that may have led to
over or under-estimation of the trachoma problem. Overestima-
tion may have occurred as a result of purposefully selecting villages
to be likely to have trachoma, as recommended by the TRA
methodology [12]. The proportions of individuals with trachoma
signs in the present study villages are therefore likely to be higher
than the overall prevalences for each county. Sensitization visits to
survey villages before the survey and the use of central point
registration may also have resulted in an overestimate of trachoma
signs, particularly TT and CO, as women with these eye problems
Table 3. Results from clinical diagnosis of active trachoma compared to NAAT.
Clinical examination result Children age 1–9 years Women age $15 years Total No.
NAAT +ve No. (%) NAAT 2ve No. (%) Total No. NAAT +ve No. (%) NAAT 2ve No. (%) Total No.
Active trachoma
* +ve 97 (46.6) 111 (53.4) 208 16 (19.0) 68 (81.0) 84 292
Active trachoma
* 2ve (Control type 1) 3 (12.5) 21 (87.5) 24 2 (11.1) 16 (88.9) 18 42
Control type 2 0 (0.0) 13 (100.0) 13 0 (0.0) 14 (100.0) 14 27
*TF and/or TI.
doi:10.1371/journal.pone.0013138.t003
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to participate in the survey than those with no eye conditions [17].
Given that TRAs were designed to provide a worst-case estimate
of the trachoma problem in a particular area, these implications of
the study design are generally well understood [17]. However,
TRA methodology also relies anecdotal information on the
presence of trachoma to assist with the identification of villages
to be assessed. Unfortunately we found that the understanding of
trachoma signs and symptoms was often limited, even among
health workers, which may have led to exclusion of highly
trachoma endemic villages from the TRA, in turn leading to an
underestimate of the problem. Such underestimate may have also
resulted from lack of accessibility; fieldwork was conducted during
the rainy season, meaning that many villages could not be
reached. It is possible that these inaccessible villages had worse
access to healthcare and clean water and may therefore have been
more affected by trachoma.
Conclusion
Unity State should be prioritized for further trachoma
interventions. Initially a PBPS will be required to generate
baseline prevalence data, to allow monitoring and evaluation of
subsequent intervention. The survey should be accompanied by
administration of household questionnaires, to get a better
understanding of the environmental and behavioural risk factors
for trachoma in this primarily Nuer-inhabited area. In Northern
Bahr-el-Ghazal State trachoma is not a major public health
problem, but efforts should be made to provide antibiotic
treatment to individuals with signs of active trachoma on a case-
by-case basis and to provide access to surgery for patients with
trichiasis. The northern part of Warrap State, which lies between
Unity and Northern Bahr-el-Ghazal States, would benefit from a
TRA to provide insight as to how far trachoma extends to the west
from Unity State.
Collection of samples to be examined with the APTIMA
Combo-2 NAAT is feasible in the context of Southern Sudan,
largely because no cold chain is required if samples are processed
within 60 days. However, within this period samples need to be
shipped to an adequately equipped laboratory, which is currently
not available in Southern Sudan. Conducting NAATs such as the
APTIMA does, however, considerably increase survey expenses.
With the kit used here, the costs of a swab collection tube and
processing of each sample was about US$ 1.25 and US$ 20,
respectively. These costs could, however, be reduced if samples
were pooled for analysis [41]. While a NAAT is likely to be a
useful complementary tool, both for evaluation of the impact of
antibiotic MDA and to assess the requirement of MDA in hypo-
endemic areas, the use of such type of test should be carefully
assessed in the context of present resource constraints – for now
resources may be better used by conducting further TRAs aimed
at establishing the scale of the trachoma problem in Southern
Sudan.
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